Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
Blocking oncogenic signaling induced by the BRAFV600E mutation is a promising approach for melanoma treatment. We tested the anti-tumor effects of a specific inhibitor of Raf protein kinases, PLX4032/RG7204, in melanoma cell lines. PLX4032 decreased signaling through the MAPK pathway only in cell lines with the BRAFV600E mutation. Seven out of 10 BRAFV600E mutant cell lines displayed sensitivity based on cell viability assays and three were resistant at concentrations up to 10 muM. Among the sensitive cell lines, four were highly sensitive with IC50 values below 1 muM, and three were moderately sensitive with IC50 values between 1 and 10 muM. There was evidence of MAPK pathway inhibition and cell cycle arrest in both sensitive and resistant cell lines. Genomic analysis by sequencing, genotyping of close to 400 oncogeninc mutations by mass spectrometry, and SNP arrays demonstrated no major differences in BRAF locus amplification or in other oncogenic events between sensitive and resistant cell lines. However, metabolic tracer uptake studies demonstrated that sensitive cell lines had a more profound inhibition of FDG uptake upon exposure to PLX4032 than resistant cell lines. In conclusion, BRAFV600E mutant melanoma cell lines displayed a range of sensitivities to PLX4032 and metabolic imaging using PET probes can be used to assess sensitivity.
Søndergaard
Jonas N
JN
Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Nazarian
Ramin
R
Wang
Qi
Q
Guo
Deliang
D
Hsueh
Teli
T
Mok
Stephen
S
Sazegar
Hooman
H
MacConaill
Laura E
LE
Barretina
Jordi G
JG
Kehoe
Sarah M
SM
Attar
Narsis
N
von Euw
Erika
E
Zuckerman
Jonathan E
JE
Chmielowski
Bartosz
B
Comin-Anduix
Begoña
B
Koya
Richard C
RC
Mischel
Paul S
PS
Lo
Roger S
RS
Ribas
Antoni
A
D019943:Amino Acid Substitution / Q000235:genetics; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003952:Diagnostic Imaging; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D015894:Genome, Human / Q000235:genetics; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008545:Melanoma / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D051379:Mice; D009154:Mutation / Q000235:genetics*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology*; D000077484:Vemurafenib; D023041:Xenograft Model Antitumor Assays
D007211:Indoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; D019869:Phosphatidylinositol 3-Kinases; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D051057:Proto-Oncogene Proteins c-akt
Nat Med. 2008 Jul;14(7):783-8
18542051
Curr Opin Oncol. 2008 Mar;20(2):183-9
18300768
Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2301s-2307s
16609049
J Biol Chem. 2002 Nov 29;277(48):46408-14
12351627
Int Immunol. 2009 Feb;21(2):155-65
19106231
Mol Cell. 2005 Jan 21;17(2):215-24
15664191
Mol Cell. 2009 Jan 30;33(2):237-47
19187764
Cancer Res. 2009 Apr 15;69(8):3241-4
19351826
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12932-7
19625624
Oncogene. 2003 Dec 18;22(58):9217-24
14681681
Nature. 2002 Jun 27;417(6892):949-54
12068308
Genome Res. 2007 Nov;17(11):1665-74
17921354
Nature. 2010 Mar 18;464(7287):427-30
20179705
N Engl J Med. 2005 Nov 17;353(20):2135-47
16291983
J Clin Oncol. 2007 Apr 20;25(12):1606-20
17443002
Nature. 2007 Feb 22;445(7130):851-7
17314971
Cancer Res. 2008 Aug 1;68(15):6145-53
18676837
Cancer Res. 2008 Jun 15;68(12):4853-61
18559533
Mol Cancer Res. 2008 May;6(5):751-9
18458053
Nat Genet. 2007 Mar;39(3):347-51
17293865
Oncogene. 2008 May 22;27(23):3301-12
18246127
Cell. 2010 Jan 22;140(2):209-21
20141835
Cell. 2004 Mar 19;116(6):855-67
15035987
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6
18287029
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24
19251651